Anti-CD30 CAR T Cells as Consolidation After HSCT for High-Risk CD30+ Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study
Lancet Haematol 2024 Mar 28;[EPub Ahead of Print], NS Grover, G Hucks, ML Riches, A Ivanova, DT Moore, TC Shea, MB Seegars, PM Armistead, KA Kasow, AW Beaven, C Dittus, JM Coghill, KJ Jamieson, BG Vincent, WA Wood, C Cheng, JK Morrison, J West, T Cavallo, G Dotti, JS Serody, B SavoldoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.